Navigation Links
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
Date:5/6/2011

SAN DIEGO, May 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Bank of America Merrill Lynch 2011 Health Care Conference on Wednesday, May 11, 2011, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) at the Encore at the Wynn Las Vegas Hotel in Las Vegas, Nevada. Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Lorcaserin Development, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
2. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
3. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
5. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
6. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
8. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
11. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... 2015  Cleveland Clinic President Wael Barsoum , ... month that industry is compelled to adopt declining reimbursements ... efficiencies—and develop the transformational innovations -- required to thrive ... preceded by Doug Kohrs , past President and ... stressed that industry must add "episode of care," also ...
(Date:7/30/2015)... , July 30, 2015 Future ... report titled, "Continuous Glucose Monitoring Systems Market: Global Industry ... the report, the global continuous glucose monitoring systems market ... is expected to reach US$ 788.4 Mn by 2020, ... 2015 to 2020. Global continuous glucose monitoring ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... presented at 2008 ICAAC/IDSA Joint Meeting, ... a,clinical-stage biopharmaceutical company focused on commercializing,products to ... the,successful demonstration of synergistic activities and improvement ... vitro combination,studies of Sequella lead TB drug ...
... PharmAthene, Inc.,(NYSE ALTERNEXT US: PIP), a biodefense ... today announced,that dosing of volunteers has begun in ... safety and tolerability in humans. Protexia(R),which is produced ... recombinant version,of human butyrylcholinesterase (BChE), which has been ...
Cached Medicine Technology:Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 2PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 3PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 4PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R) 5
(Date:7/31/2015)... ... July 31, 2015 , ... ... to know in predictive health analytics , Jvion continues to disrupt the ... creates predictive software that targets patient and population level illness to drive prevention ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... to patients and family members, medical professionals, and researchers, covering a variety of ... conference is a collaborative effort between the Mesothelioma Applied Research Foundation and Memorial ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... researchers, physicians, technologists and medical experts from across ... to explore topics in nuclear medicine, molecular imaging, ... Mid-Winter Meetings. , Four meetings were held ... Educational Symposium of the American College of Nuclear ...
... NEW YORK , Feb. 9 As part ... development of life-transforming treatments and a cure for Parkinson,s disease, ... in total funding for seven research projects aiming to push ... therapeutic development. , While new genetic and cellular targets ...
... Feb. 9 Chiquita Brands International, Inc. (NYSE: ... Fresh Produce Association Foundation,s " A Salad Bar in Every ... health commitment by Chiquita and its Fresh Express subsidiary will ... across America.  Chiquita is the first produce company to commit ...
... clinical data for nearly 800 patients with non-small cell lung ... with age and sex specific patterns of increased or decreased ... issue of JAMA . The five-year overall survival ... remains the leading cause of cancer-related death in the United ...
... People with cystic fibrosis, an inherited disease that clogs ... defy treatment. While the life expectancy for children with ... many lives are still shortened in young adulthood by ... are often caused by common, environmental microbes that mutate ...
... First Lady Michelle ... number of chronic diseases including diabetes, heart disease, osteoarthritis, and sleep apnea. ... Washington, DC (Vocus) February 9, ... a risk factor for a number of chronic diseases including diabetes, heart disease, osteoarthritis, and ...
Cached Medicine News:Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 2Health News:SNM's Conjoint Mid-Winter Meetings continue to advance molecular imaging 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 3Health News:Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinson's Drug Development 4Health News:Chiquita Announces Support for School Salad Bar Campaign 2Health News:Chiquita Announces Support for School Salad Bar Campaign 3Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 2Health News:Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer 3Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 2Health News:Adapting to clogged airways makes common pathogen resist powerful drugs 3Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 2Health News:National Wildlife Federation Says Outdoor Time for Kids Can Help First Lady Achieve Her “Let's Move” Goal 3
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Inquire...
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Inquire...
Medicine Products: